Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 190 of the 191 references it cites were found in a registry or an index; 67 of the 105 sources its claims cite were checked for support.

Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review

Open access
Li, Yu, Zhang, Cangang, Jiang, Aimin, Lin, Anqi, Liu, Zaoqu, Cheng, Xiangshu, Wang, Wanting, Cheng, Quan, Zhang, Jian, Wei, Ting, Luo, Peng · 2024 · Journal of Translational Medicine

Abstract

Regulatory T cells (Tregs) expressing the transcription factor FoxP3 are essential for maintaining immunological balance and are a significant component of the immunosuppressive tumor microenvironment (TME). Single-cell RNA sequencing (ScRNA-seq) technology has shown that Tregs exhibit significant plasticity and functional diversity in various tumors within the TME. This results in Tregs playing a dual role in the TME, which is not always centered around supporting tumor progression as typically believed. Abundant data confirms the anti-tumor activities of Tregs and their correlation with enhanced patient prognosis in specific types of malignancies. In this review, we summarize the potential anti-tumor actions of Tregs, including suppressing tumor-promoting inflammatory responses and boosting anti-tumor immunity. In addition, this study outlines the spatial and temporal variations in Tregs function to emphasize that their predictive significance in malignancies may change. It is essential to comprehend the functional diversity and potential anti-tumor effects of Tregs to improve tumor therapy strategies.

Overview

CoChat Summary

## TL;DR

This review argues that regulatory T cells (Tregs) in the tumor microenvironment are not uniformly pro-tumor; instead, some Treg subpopulations can support anti-tumor immunity or suppress tumor-promoting inflammation. It also emphasizes that Tregs’ prognostic and therapeutic significance varies by tumor type, location, and stage.

## Key findings

  • The review summarizes evidence that Tregs can have anti-tumor effects through two main routes: boosting anti-tumor immunity and suppressing tumor-promoting inflammation.
  • Single-cell RNA sequencing is highlighted as showing substantial Treg plasticity and heterogeneity; the paper describes stable, unstable, fragile, Th1-like, Th17-like, and other Treg subgroups.
  • In several cancers, higher Treg infiltration is linked with better outcomes: the paper cites colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and gastric cancer (GC), and reports a 52% greater chance of survival in HER2+/ER− breast cancer patients with higher CD8+ T cells and increased FoxP3+ Treg infiltration.
  • Prognostic effects vary by context: in pancreatic cancer, one cited study found higher Tregs associated with shorter OS/DFS, while another found significant Treg infiltration extended survival; in gastric cancer, early-stage (I–II) high FoxP3+ Treg infiltration was associated with better 5-year survival, whereas stage III–IV was associated with worse prognosis.

## Methods

  • Narrative review of published studies on Tregs in the tumor microenvironment, with emphasis on single-cell RNA sequencing, spatial heterogeneity, and functional subgrouping of Tregs.
  • The paper synthesizes findings across multiple tumor types and cites both clinical studies and preclinical models (including mouse models) to support proposed mechanisms.
  • Main analysis is qualitative and integrative: it groups reported Treg effects into anti-tumor immunity and suppression of tumor-promoting inflammation, then discusses prognostic heterogeneity by tumor type, tumor region, and tumor stage.

## Limitations

  • The paper states that many of the studies analyzed focused solely on clinical data, and it calls for more work on the biological basis of Tregs in cancer.
  • It states that few studies have examined the correlation between tumor stage and Tregs function, so the stage-specific relationship remains insufficiently understood.
  • Evident from the text: this is a review, so its conclusions depend on heterogeneous prior studies with differing markers, tumor types, and definitions of Tregs; the paper itself notes that current markers are often insufficient to distinguish functional subgroups accurately.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12967-024-05104-y

Cites

190 of 190 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Three subgroups can be identified based on phenotype and function of Tregs. Stable Tregs: express FoxP3, have immunosuppressive function; Unstable Tregs: express low or no FoxP3 that secrete IFN-γ and can promote anti-tumor immunity; Fragile Tregs: express FoxP3 while secreting IFN-γ, and have anti-tumor activity [30]
Fig. 1 Three subgroups can be identified based on phenotype and function of Tregs. Stable Tregs: express FoxP3, have immunosuppressive function; Unstable Tregs: express low or no FoxP3 that secrete IFN-γ and can promote anti-tumor immunity; Fragile Tregs: express FoxP3 while secreting IFN-γ, and have anti-tumor activity [30]CC BY · PubMed Central
Fig. 2 Potential anti-tumor mechanisms of Tregs. A Pro-inflammatory Tregs secrete inflammatory cytokines that have anti-tumor effects. B IL-10 secreted by Tregs promotes the activation of CD8+ T cells and induces the production of GzmB and IFN-γ, and further upregulates the expression of MHC molecules. C MCs release mediators that promote tumor metastasis and angiogenesis. Tregs decrease MC numbers and hinder their degranulation by releasing IL-10 and via the OX40-OX40L cell contact mechanism. D Th2 promotes aberrant expression of β-catenin, releases cytokines that activate M2 macrophages, and promotes tumor-associated fibrous capsule development, whereas Th17 releases cytokines that stimulate tumor angiogenesis and progression. Tregs suppress the pro-tumor inflammatory response induced by Th2, Th17, and M2 macrophages. E Tregs promote the differentiation of fibroblasts to myofibroblasts by releasing TGF-β, in turn suppressing tumor growth. Depletion of Tregs cells leads to an increase in the accumulation of fibroblasts and the recruitment of tumor-promoting Arg1+ Mφ cells
Fig. 2 Potential anti-tumor mechanisms of Tregs. A Pro-inflammatory Tregs secrete inflammatory cytokines that have anti-tumor effects. B IL-10 secreted by Tregs promotes the activation of CD8+ T cells and induces the production of GzmB and IFN-γ, and further upregulates the expression of MHC molecules. C MCs release mediators that promote tumor metastasis and angiogenesis. Tregs decrease MC numbers and hinder their degranulation by releasing IL-10 and via the OX40-OX40L cell contact mechanism. D Th2 promotes aberrant expression of β-catenin, releases cytokines that activate M2 macrophages, and promotes tumor-associated fibrous capsule development, whereas Th17 releases cytokines that stimulate tumor angiogenesis and progression. Tregs suppress the pro-tumor inflammatory response induced by Th2, Th17, and M2 macrophages. E Tregs promote the differentiation of fibroblasts to myofibroblasts by releasing TGF-β, in turn suppressing tumor growth. Depletion of Tregs cells leads to an increase in the accumulation of fibroblasts and the recruitment of tumor-promoting Arg1+ Mφ cellsCC BY · PubMed Central
Fig. 3 Spatiotemporal heterogeneity of Tregs function in TME. A In non-inflammatory tumors, Tregs mainly inhibit anti-tumor immunity. Conversely, in inflammatory tumors, Tregs tend to improve prognosis by suppressing tumor-promoting inflammation. B There exist variances in the function of Tregs in the tumor nests as compared to those in the mesenchyme. C As the tumor progressed, TNFRSF9− Tregs transformed into TNFRSF9+ Tregs, leading to a gradual enhancement of their immunosuppressive abilities
Fig. 3 Spatiotemporal heterogeneity of Tregs function in TME. A In non-inflammatory tumors, Tregs mainly inhibit anti-tumor immunity. Conversely, in inflammatory tumors, Tregs tend to improve prognosis by suppressing tumor-promoting inflammation. B There exist variances in the function of Tregs in the tumor nests as compared to those in the mesenchyme. C As the tumor progressed, TNFRSF9− Tregs transformed into TNFRSF9+ Tregs, leading to a gradual enhancement of their immunosuppressive abilitiesCC BY · PubMed Central
Fig. 4 Future perspectives of Tregs in TME
Fig. 4 Future perspectives of Tregs in TMECC BY · PubMed Central

Verification

Claims the paper makes

49 Valid · 7 Not valid · 29 Not checked · 24 Own results and interpretations

55 more claims · 23 with their cited sources checked

Create a free account to see all 109 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 47
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 191 references

Cited by

See all 105

Metadata

Authors
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., & Luo, P.
Affiliations
  • Zhujiang Hospital (CN)
  • Xi'an Jiaotong University (CN)
  • Second Military Medical University (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Harbin Medical University (CN)
  • Central South University (CN)
Corresponding author
  • Cheng, Quan
  • Zhang, Jian
  • Wei, Ting
  • Luo, Peng
Venue
Journal of Translational Medicine
Published
2024-03-20
Volume
22
Issue
1
Pages
293-293
ISSN
1479-5876 (ISSN-L)
OpenAlex
W4393011526
Cited by
105
References
191
Citations by year
2026: 34 · 2025: 55 · 2024: 15
FWCI
15.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Natural Science Foundation of Guangdong Province (2018A030313846, 2021A1515012593)
  • Science and Technology Planning Project of Guangdong Province (2019A030317020)
  • the National Natural Science Foundation of China (81802257, 81871859, 81772457, 82172750, 82172811, 82260546)
  • Guangdong Basic and Applied Basic Research Foundation (2022A1515111212)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
regulatory T cells, Foxp3, tumor microenvironment, antitumor immunity, immunosuppression, Treg plasticity, Treg heterogeneity, tumor inflammation
MeSH terms
Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Regulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. https://app.cochat.ai/papers/10.1186/s12967-024-05104-y
The paper
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., & Luo, P. (2024). Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. Journal of Translational Medicine. https://doi.org/10.1186/s12967-024-05104-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.